Identifying drug innovations on the brink of reaching the market

New York, October 13, 2006 – Revere Data, LLC, a fast-growing provider of independent research data and investment analytics, today announced a new Revere Report that identifies companies developing late clinical stage NME (New Molecular Entities) on the brink of reaching the market.

The Emerging Biopharm Therapeutics Report is designed to generate ideas for trading and investment opportunities in the Biopharmaceuticals sector. The report is available to current Revere subscribers and for sale on Revere’s website.

“While the FDA approves around 100 drugs each year, more than 75% of them are ‘me too’ drugs that lack true innovation,” noted Brian Hill, Director of Research for Revere. “This report is developed to highlight innovative drug candidates that work significantly different than today’s approved therapeutics, and how Revere can help investors identify them in near-time through its patented classification system and proprietary drug database.”

Specifically, the Emerging Biopharm Therapeutics Report identifies a list of 41 Biotech, Specialty Pharma and Big Pharma companies either with NME drugs in Phase III trials or which have received FDA Approvable Letters, along with detail on each NME candidate’s:

* tradename and indication
* mechanism of action
* key upcoming clinical/regulatory catalysts

“Blockbuster returns in the Biopharmaceuticals sector have always been driven by breakthrough NME,” said Kevin O’Brien, Chief Executive Officer of Revere, “ but the challenge is to identify them at the right moment—early enough before the expectations are priced in, but late enough in clinical stage development when they present a much higher probability of success. The average YTD return of the 41 companies profiled in this report has been 11.42%, outperforming the Nasdaq Biotechnology Index (NBI) by 13.01% for the same period.” Some of the companies profiled in this report include Acorda Therapeutics, AnorMED, KOS Pharmaceuticals, Merck, Amgen and Pfizer.


Revere Data, LLC, provides finance and business professionals with superior data and analytics for companies traded publicly on U.S. exchanges. The Revere Data approach is based on precise product and industry classification and identification of key business relationships. Revere Data’s datafeeds and its research and real-time trading applications feature unique content derived from Revere Data’s own independent research: the Revere Hierarchy™, a patented classification system that provides unmatched detail in specifying a company’s business activities and identifying exact competitors, and Revere Relationships™, a database mapping a company to its key competitors, customers, suppliers, and strategic partners. For more information, please visit www.reveredata.com.